Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
Open Access
- 20 June 2018
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 11 (1) , 1-13
Abstract
Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive. Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was generated to investigate the drug efficacy in metastasis. Blockade of Src kinase activity by saracatinib effectively suppressed invasion and metastasis of HNSCC. Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins. In tests in mice, saracatinib loaded into the novel multifunctional nanoparticles exhibited superior effects on suppression of HNSCC metastasis compared with the free drug, which is mainly attributed to highly specific and efficient tumor-targeted drug delivery system. These findings and advances are of great importance to the development of Src-targeted nanomedicine as a more effective therapy for metastatic HNSCC.Keywords
This publication has 53 references indexed in Scilit:
- Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast CancerClinical Breast Cancer, 2011
- Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- pH-Responsive Nanoparticles for Drug DeliveryMolecular Pharmaceutics, 2010
- Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenograftsBMC Cancer, 2010
- Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation TransportersCancer Research, 2010
- Increased expression of Cathepsin B in oral squamous cell carcinomaInternational Journal of Oral and Maxillofacial Surgery, 2010
- Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2009
- Nanoparticle-based targeted drug deliveryExperimental and Molecular Pathology, 2009
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma CellsMolecular Cancer Research, 2008
- Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cellsBreast Cancer Research and Treatment, 2005